title: Receptor expression in orbital inflammatory syndromes and implications for targeted therapy.
abstract: To investigate the expression of multiple therapeutic targets in tissue specimens from patients with orbital inflammatory syndromes, the clinical records of 16 patients treated for orbital inflammation between January 2003 and November 2005 for whom tissue blocks were available were reviewed retrospectively. Immunohistochemical staining was performed on archived specimens using commercially available monoclonal antibodies against CD3, CD20, CD22, CD23, CD25, and CD52 antigens. The histologic diagnoses were confirmed, and the immunohistochemical staining patterns were agreed upon by both collaborating pathologists (JLJ and PC-B). The study included 13 women and 3 men who ranged in age from 4 to 79 years (mean, 46 years). The histologic diagnoses were as follows: orbital pseudotumor in six patients; sarcoidosis, three; eosinophilic granuloma, one; necrobiotic xanthogranuloma, one; nonspecified granulomatous inflammation, one; Graves' ophthalmopathy, one; Wegener's granulomatosis, one; and reactive lymphoid hyperplasia, two. One orbital lymphoma specimen and one foreign body reaction specimen were used as controls. CD20 was strongly expressed in all specimens except three (Wegener's granulomatosis, eosinophilic granuloma, and nonspecified granulomatous inflammation specimens), and CD25 was strongly expressed in all specimens except the Wegener's granulomatosis specimen, in which this antigen was only moderately expressed. CD20 and CD25 were strongly or moderately expressed in most of the tested specimens of orbital inflammation. If our findings are confirmed in a larger study, rituximab, which targets CD20, and denileukin diftitox (ONTAK), which targets CD25, should be considered for future clinical trials for orbital inflammatory syndromes.
authors.affiliation: Section of Ophthalmology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: V H
authors.initials: VH
authors.lastname: Ho
authors.forename: P
authors.initials: P
authors.lastname: Chevez-Barrios
authors.forename: J L
authors.initials: JL
authors.lastname: Jorgensen
authors.forename: R Z
authors.initials: RZ
authors.lastname: Silkiss
authors.forename: R Z
authors.initials: RZ
authors.lastname: Silkis
authors.forename: B
authors.initials: B
authors.lastname: Esmaeli
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015703:Antigens, CD / Q000096:biosynthesis* / Q000235:genetics*; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007249:Inflammation / Q000276:immunology / Q000378:metabolism / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009916:Orbital Diseases / Q000276:immunology / Q000473:pathology* / Q000628:therapy*; D016727:Orbital Pseudotumor / Q000276:immunology / Q000473:pathology / Q000628:therapy; D012189:Retrospective Studies; D013577:Syndrome
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD